Question explored with the scientific record
Is gene therapy for muscle spasticity available?
The short version: no gene therapy for muscle spasticity is clinically available. The evidence is all preclinical, mostly in rats and mice, and none of it targets spasticity directly.
The retrieved studies test gene therapy for neuropathic pain [4, 6, 11], spinal cord injury recovery [10], motor neuron disease [5, 7], and metabolic disorders [8]. None measure spasticity as an outcome. The closest is the 2025 KCC2 study in rats with cervical spinal cord injury, which improved motor function but did not report spasticity [10]. That study was funded by academic grants, not a manufacturer, but it is a single rat experiment with group sizes of 3-6 animals per condition.
The delivery technology exists: intrathecal AAV9 can transduce spinal motor neurons in pigs [5] and non-human primates [8]. But translating that into a safe, durable treatment for spasticity in humans requires trials that have not been run. The 2025 adrenomyeloneuropathy review notes a phase 1 trial is planned with results expected in 2028 [8]. That is the only human timeline in the evidence, and it targets a different condition.
My call: gene therapy for muscle spasticity is not available and has not been tested in humans for that indication.
Sources used 14
-
Genetic and clinical aspects of X-linked hydrocephalus (L1 disease): Mutations in the L1CAM gene
This paper reviews the genetic and clinical landscape of X-linked hydrocephalus (L1 disease) caused by L1CAM mutations, detailing the mutation spectrum, genotype–phenotype correlations, diagnostic relevance, and implications for genetic counseling.
DOI: 10.1002/humu.1144 -
296. Longitudinal Surveillance of Non Human Primate Recipients of Intrauterine Gene Transfer for Coagulation Factor Deficiencies
A multi-part study evaluating AAV-based gene delivery approaches for fetal and postnatal monogenic diseases—comparing intrathecal pump versus bolus CNS delivery, assessing AAV9-ELA therapy in hypertensive rats, and characterizing a novel anti-sense promoter element near the AAV …
DOI: 10.1016/s1525-0016(16)33105-7 -
Spinal gene transfer using ultrasound and microbubbles
This study demonstrates that percutaneous ultrasonication combined with intrathecal injection of plasmid DNA and microbubbles significantly enhances gene transfer into spinal meningeal cells in mice, offering a minimally invasive approach for spinal gene therapy.
DOI: 10.1016/j.jconrel.2006.10.026 -
Interleukin-2 gene therapy of chronic neuropathic pain
This study investigates the antinociceptive effects of intrathecal delivery of human interleukin-2 gene therapy in a rat model of chronic neuropathic pain, demonstrating prolonged pain relief compared to direct IL-2 protein administration.
DOI: 10.1016/s0306-4522(02)00078-7 -
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs
This study demonstrates the successful intrathecal delivery of AAV9 in pigs, resulting in robust transduction of spinal motor neurons across multiple spinal cord segments, which has implications for gene therapy in motor neuron diseases.
DOI: 10.1038/gt.2011.130 -
Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic pain
A two-injection, non-viral gene therapy paradigm using naked plasmid DNA encoding IL-10 (F129S) applied intrathecally in rats requires an immunological priming step and continuous IL-10 signaling to produce long-term reversal of neuropathic pain, revealing a mechanism in which i…
DOI: 10.1038/gt.2009.79 -
Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis
This study demonstrates that intrathecal injection of recombinant adeno-associated virus (rAAV) serotypes, particularly rAAVrh10 and rAAV9, can achieve widespread transduction in the central nervous system and deliver effective RNA interference therapy targeting the SOD1 gene in…
DOI: 10.1093/hmg/ddt454 -
Gene Therapy of Adrenomyeloneuropathy: Challenges, Target Cells, and Prospectives
This review analyzes AAV-based gene therapy approaches for X-linked adrenoleukodystrophy–associated adrenomyeloneuropathy (AMN), detailing target cell populations (oligodendrocytes, astrocytes, DRG neurons), delivery routes (IV, intrathecal, intra-cisterna magna, intracerebroven…
DOI: 10.3390/biomedicines13081892 -
Antisense Oligonucleotide Gene Therapy for Neuromuscular Disorders
Antisense oligonucleotide gene therapy shows promise for neuromuscular disorders by modulating RNA transcripts to downregulate disease-causing proteins or alter splicing, with notable successes in SMA and DMD but ongoing challenges in cost, CNS delivery, and long-term safety.
DOI: 10.18192/uojm.v8i2.3462 -
AAV9-mediated KCC2 upregulation enhances functional recovery following cervical spinal cord injury
This translational rat study shows that intrathecal AAV9-mediated upregulation of KCC2 at the site of cervical spinal cord injury normalizes inhibitory neurotransmission, reduces aberrant forelimb neurophysiology, and enhances long-term forelimb and hindlimb functional recovery …
DOI: 10.1038/s42003-025-08734-0 -
Development of Recombinant Anti-TLR2 Antibodies and PLGA Nanoparticle-based Gene Therapy for the Treatment of Neuropathic Pain
This study develops recombinant anti-TLR2 antibodies (nanobody nb52, nb52 dimer, scFv33, scFv1) and employs biodegradable PLGA nanoparticles to deliver their genes intrathecally in mouse models of neuropathic and inflammatory pain, achieving long-lasting analgesia and reduced sp…
DOI: 10.1101/2025.11.13.688281 -
Synthesis of bifunctional molecules containing [12]aneN 3 and coumarin moieties as effective DNA condensation agents and new non-viral gene vectors
A two-step synthesis yields bifunctional small molecules that combine a macrocyclic [12]aneN3 unit with coumarin moieties, which condense plasmid DNA and function as low-toxicity non-viral gene vectors, with 4b and 5b showing notable DNA condensation, cellular uptake, and transf…
DOI: 10.1039/c4ob02676d -
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B
This study demonstrates the efficacy of peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B, achieving sustained therapeutic levels of factor IX in hemophilia B dogs without the development of inhibitory antib…
DOI: 10.1182/blood-2009-12-261156 -
Gene delivery efficiency and intracellular trafficking of novel poly(allylamine) derivatives
This study develops novel poly(allylamine) derivatives that enhance gene delivery efficiency while reducing cytotoxicity, demonstrating their potential as effective non-viral gene carriers.
DOI: 10.1016/j.ijpharm.2014.11.053